Lupus for Researchers

    No news available.

Novartis Investigational Checkpoint Inhibitor Tislelizumab Met Primary Endpoint of Overall Survival in Pivotal Phase III Trial of Esophageal Cancer After Systemic Therapy

EAST HANOVER, N.J., June 4, 2021 -- Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus...

Read More

Anifrolumab Showed Benefit Across Different Measures of Skin and Joint Disease Activity in Patients with Systemic Lupus Erythematosus

2 June 2021 - A new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin...

Read More